Altimmune Inc. Watch

from S-3ASR 46 pages Equity Distribution Agreement

from 8-K 41 pages Altimmune, Inc. Equity Distribution Agreement

from 8-K 50 pages 3,369,564 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,630,436 Shares of Common Stock Altimmune, Inc. Underwriting Agreement

from 8-K 36 pages Altimmune, Inc. $50,000,000 Common Stock Equity Distribution Agreement Dated: March 27, 2020

from 8-K 34 pages Placement Agency Agreement

from 8-K 28 pages Placement Agency Agreement

from S-1/A 36 pages [•] Common Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock [•] Pre-Funded Units, Each Consisting of a Pre-Funded Warrant to Purchase One Share of Common Stock and a Warrant to Purchase One Share of Common Stock Altimmune, Inc. Underwriting Agreement

from 8-K 33 pages Placement Agency Agreement

from 8-K 53 pages 15,656 Series B Convertible Preferred Shares Warrants to Purchase 2,345,427 Common Shares Altimmune, Inc. Preferred Stock Placement Agency Agreement

from S-3 3 pages Pharmathene, Inc. Controlled Equity Offeringsm Amendment No. 1 to Sales Agreement

from 8-K 25 pages Pharmathene, Inc. Placement Agency Agreement

from 8-K 5 pages [Form]early Conversion Agreement

from 8-K 26 pages Pharmathene, Inc. 4,300,000 Shares of Common Stock Underwriting Agreement

from 8-K 20 pages Confidential

from 8-K 19 pages Confidential

from 8-K 8 pages This Letter Agreement (This “Agreement”) Confirms Our Understanding That Pharmathene, Inc. (The “Company”), Has Retained Caris & Co. (The “Placement Agent”) to Act as the Company’s Agent, on a Non-Exclusive Basis (To Serve as a Co-Manager With Rodman & Renshaw, LLC (“Rodman”) as Lead Manager) in Connection With the Proposed Public Placement (The “Transaction”) of Registered Securities (The “Securities”) of the Company, Consisting of Shares (The “Shares”) of the Company’s Common Stock, Par Value $0.001 Per Share (The “Common Stock”). the Terms of Such Transaction and the Securities Shall Be Mutually Agreed Upon by the Company and the Purchasers (Each a “Purchaser” and Collectively, the “Purchasers”), and Nothing Herein Constitutes an Agreement of the Parties That the Placement Agent Would Have the Power or Authority to Bind the Company or Any Purchaser or an Obligation for the Company to Issue Any Securities or Complete the Transaction. the Placement Agent’s Engagement Hereunder Will Be for the Period of 30 Days, Unless Extended by the Parties. the Engagement May Be Terminated by Either the Company or the Placement Agent at Any Time Upon 10 Days’ Written Notice

from 8-K 16 pages Confidential

from SC 13D/A 2 pages Identity and Background of Bsam’s Directors and Officers

from SC 13D/A 3 pages Identity and Background of Tbsci’s Directors and Officers

from SC 13D 2 pages Identity and Background of Bsam’s Directors and Officers